Harvest Technologies Signs a Co-Promotion Agreement With LifeCell Corporation For The SmartPRep(R) Platelet Concentration System in the Hospital ENT, Plastic and Soft Tissue Surgery Markets

    PLYMOUTH, Mass., Sept. 17 /PRNewswire/ -- Harvest Technologies
 Corporation announced today that it signed an agreement with
 LifeCell Corporation (Nasdaq:   LIFC) granting LifeCell the exclusive right for
 the co-promotion of the SmartPReP system in the United States to hospital
 based ENT, plastic and general surgeons.  Harvest will continue to market and
 distribute the SmartPRep system to the dental, chronic wound and private
 clinic plastic and ENT markets.  DePuy AcroMed, Inc., a Johnson & Johnson
 company currently distributes the SmartPReP system worldwide under the name
 Symphony in the hospital based spinal, orthopedic and sports medicine markets.
     Harvest Technologies goal is to improve surgical outcomes by harvesting,
 concentrating and providing to the clinician proteins that act to accelerate
 the wound healing process. The technology is completely automated, requires
 only 15 minutes, uses only a small sample of the patient's blood (20 cc) and
 is performed at point of care.  Harvest's SmartPRep System incorporates the
 Company's proprietary floating shelf disposable technology and a proprietary
 decanting centrifuge. The systems performance is completely independent of the
 operator due to the combination of the floating shelf disposable and a totally
 automated approach. This assures a consistent and reliable wound healing
 protein load yielding predictable clinical outcomes."
     Mr. Kevin Benoit, General Manager of Harvest stated: "Predictability and
 efficacy of regenerative treatments are the two most important factors for
 improved medical outcomes. Additional factors include offering medical
 professionals a cost-effective approach with a technology that is safe and
 easy to implement. We believe, interest in autologous, affordable, easy to use
 products like the Harvest SmartPReP System to provide the clinician the
 ability of regenerating damaged tissue, represents a large potential untapped
 market.  Preliminary distribution activities are already underway across the
 United States and physicians are expressing their enthusiasm for the system's
 safety and cost efficiencies as well as the technology's future possibilities.
 A national release is planned for later this year."
     Harvest Technologies develops, manufactures and markets the SmartPReP
 System for the preparation and application of a biomaterial comprised of
 concentrations of wound healing proteins. The SmartPReP System is the only
 commercially available product that offers a customer the ability to produce
 consistently high dose of growth factor proteins across a diverse patient and
 operator population with automated easy to use format.
     LifeCell Corporation develops and markets biologic products for the repair
 or replacement of damaged or inadequate tissues. The Company's core
 preservation technology produces an acellular tissue matrix, which retains the
 essential biochemical and structural components necessary for normal tissue
 regeneration. LifeCell currently markets three products based on its tissue
 matrix technology: AlloDerm(R) for the plastic reconstructive, burn, and
 dental markets; Cymetra(TM) for the plastic reconstructive and dermatology
 markets; and Repliform(TM) for the urogynecology market through its
 partnership with Boston Scientific Corporation.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X17165181
 
 

SOURCE  Harvest Technologies Corporation